State Street Corp Gemini Therapeutics, Inc. Transaction History

State Street Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.22 - $1.73 $374,302 - $530,772	-306,805 Reduced 75.07%	101,899 $172,000
Q1 2022 May 16, 2022	SELL	$1.29 - $3.08 $4,529 - $10,813	-3,511 Reduced 0.85%	408,704 $568,000
Q4 2021 Feb 14, 2022	SELL	$2.39 - $4.0 $7,399 - $12,384	-3,096 Reduced 0.75%	412,215 $1.2 Million
Q3 2021 Nov 15, 2021	BUY	$3.3 - $6.32 $353,661 - $677,314	107,170 Added 34.78%	415,311 $1.68 Million
Q2 2021 Aug 16, 2021	BUY	$6.32 - $14.02 $1.83 Million - $4.06 Million	289,341 Added 1539.05%	308,141 $1.99 Million
Q1 2021 May 17, 2021	BUY	$11.32 - $18.0 $212,816 - $338,400	18,800 New	18,800 $255,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.